<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00860925</url>
  </required_header>
  <id_info>
    <org_study_id>POISE-2 01 2009</org_study_id>
    <nct_id>NCT00860925</nct_id>
  </id_info>
  <brief_title>PeriOperative ISchemic Evaluation-2 Pilot</brief_title>
  <acronym>POISE2-pilot</acronym>
  <official_title>PeriOperative ISchemic Evaluation-2 (POISE-2) Trial: A Pilot</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Physicians' Services Incorporated Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Network and Centre for Trials Internationally</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Major non-cardiac surgeries are common and major heart problems during or after such&#xD;
      surgeries represent a large population health problem. Few treatments to prevent heart&#xD;
      problems around the time of surgery have been tested.&#xD;
&#xD;
      There is encouraging data suggesting that low-doses of Acetyl-Salicylic Acid (ASA) and&#xD;
      Clonidine, which are two medications, given individually for a short period before and after&#xD;
      major surgeries may prevent major heart problems.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The POISE-2 Pilot Trial will provide the essential remaining feasibility data that POISE-2&#xD;
      researchers require prior to conducting a large international study to test the effect of ASA&#xD;
      and Clonidine in preventing major vascular complications during the first 30 days after&#xD;
      surgery.&#xD;
&#xD;
      The POISE-2 Pilot Trial is a factorial design randomized control trial that will compare ASA&#xD;
      to placebo and clonidine to placebo. Patients in the POISE-2 pilot trial will be randomly&#xD;
      assigned to one of four groups: ASA and Clonidine together, ASA and Clonidine placebo, ASA&#xD;
      placebo and Clonidine, or a ASA placebo and Clonidine placebo. Two to four hours prior to&#xD;
      surgery, eligible patients are given ASA study drug and Clonidine study drug orally (162mg&#xD;
      ASA or its placebo and 0.2mg Clonidine or its placebo) and a patch to apply (0.2mg/day&#xD;
      Clonidine or its placebo). The patch will remain in place for 72 hours after surgery. After&#xD;
      the surgery, patients ingest one tablet a day (81mg ASA or its placebo) for 7 days if patient&#xD;
      was were taking ASA chronically prior to surgery or for 30 days if they were not chronically&#xD;
      taking ASA prior to surgery. Troponin measurements will be collected between 6 to 12 hours&#xD;
      after the operation and on the 1st, 2nd, and 3rd days after surgery. If blood tests reveal an&#xD;
      elevation in the troponin measurement an electrocardiogram (ECG) will be undertaken&#xD;
      immediately.&#xD;
&#xD;
      Research personnel will follow patients until 30 days after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of recruiting 90 patients in 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of administering pre-operative ASA and clonidine</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary estimate of major bleeding and clinically significant hypotension</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary estimate of the composite of vascular death and non-fatal myocardial infarction.</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>active clonidine and active ASA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>active clonidine and ASA placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Clonidine placebo and active ASA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Clonidine placebo and ASA placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>active clonidine</intervention_name>
    <description>Prior to surgery (goal 2-4 hours) patients will ingest 1 tablet of clonidine (0.2 mg) and will have a transdermal clonidine patch (0.2 mg/day) applied. The patch will be removed at 72 hours after surgery.</description>
    <arm_group_label>active clonidine and ASA placebo</arm_group_label>
    <arm_group_label>active clonidine and active ASA</arm_group_label>
    <other_name>CATAPRES, CATAPRES TTS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>active ASA</intervention_name>
    <description>Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA tablets (81 mg per tablet). After the first dose, patients will ingest 1 tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take ASA orally will receive it rectally.</description>
    <arm_group_label>Clonidine placebo and active ASA</arm_group_label>
    <arm_group_label>active clonidine and active ASA</arm_group_label>
    <other_name>ENTROPHEN CHEWABLE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine Placebo</intervention_name>
    <description>Prior to surgery (goal 2-4 hours) patients will take oral clonidine placebo and will have a transdermal placebo patch applied. The patch will be removed at 72 hours after surgery.</description>
    <arm_group_label>Clonidine placebo and ASA placebo</arm_group_label>
    <arm_group_label>Clonidine placebo and active ASA</arm_group_label>
    <other_name>CATAPRES placebo and CATAPRES TTS placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASA Placebo</intervention_name>
    <description>Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA placebo tablets. After the first dose, patients will ingest 1 placebo tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take placebo orally will receive it rectally.</description>
    <arm_group_label>Clonidine placebo and ASA placebo</arm_group_label>
    <arm_group_label>active clonidine and ASA placebo</arm_group_label>
    <other_name>ENTROPHEN CHEWABLE placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients undergoing noncardiac surgery who fulfill the following criteria:&#xD;
&#xD;
          -  age ≥ 45 years&#xD;
&#xD;
          -  expected to require at least an overnight hospital admission after noncardiac surgery,&#xD;
             and fulfill any 1 of the following criteria:&#xD;
&#xD;
               -  history of coronary artery disease&#xD;
&#xD;
               -  peripheral vascular disease&#xD;
&#xD;
               -  stroke&#xD;
&#xD;
               -  undergoing major vascular surgery (i.e., vascular surgery except arteriovenous&#xD;
                  shunt, vein stripping procedures, and carotid endarterectomies)&#xD;
&#xD;
               -  OR any 3 of 9 risk criteria:&#xD;
&#xD;
                    1. undergoing major surgery [i.e., intraperitoneal, intrathoracic, or&#xD;
                       orthopedic surgery]&#xD;
&#xD;
                    2. history of congestive heart failure&#xD;
&#xD;
                    3. transient ischemic attack&#xD;
&#xD;
                    4. diabetes and currently taking an oral hypoglycemic agent or insulin&#xD;
&#xD;
                    5. age = or &gt; than 70 years&#xD;
&#xD;
                    6. hypertension&#xD;
&#xD;
                    7. serum creatinine &gt; 175 µmol/L&#xD;
&#xD;
                    8. history of smoking within 2 years of surgery, or&#xD;
&#xD;
                    9. undergoing emergent/urgent surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients has taken ASA &lt; or = to 72 hours before scheduled surgery&#xD;
&#xD;
          -  history of ASA or clonidine hypersensitivity or allergy&#xD;
&#xD;
          -  systolic blood pressure &lt; 105 mm Hg&#xD;
&#xD;
          -  heart rate &lt; 55 beats per minute&#xD;
&#xD;
          -  second or third degree heart block without a pacemaker&#xD;
&#xD;
          -  patient has active peptic ulcer disease&#xD;
&#xD;
          -  Patient has had a bare metal stent in the six weeks prior to randomization&#xD;
&#xD;
          -  Patient has had a drug eluting stent in the year prior to randomization&#xD;
&#xD;
          -  Patient is currently taking an alpha-2 agonist, alpha methyldopa, reserpine,&#xD;
             clopidogrel, or ticlopidine&#xD;
&#xD;
          -  Patient undergoing intracranial surgery, carotid endarterectomy, or retinal surgery&#xD;
&#xD;
          -  Surgeon unwilling to have patient participate in a participate in a perioperative&#xD;
             clonidine/ASA trial&#xD;
&#xD;
          -  Prior enrolment in the POISE-2 pilot trial&#xD;
&#xD;
          -  Unable to obtain or refusal to consent prior to surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>P. J. Devereaux, MD FRCP PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter C MacKenzie Health Sciences</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Joseph's Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>March 12, 2009</study_first_submitted>
  <study_first_submitted_qc>March 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2009</study_first_posted>
  <last_update_submitted>March 8, 2010</last_update_submitted>
  <last_update_submitted_qc>March 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr P.J. Devereaux</name_title>
    <organization>McMaster University</organization>
  </responsible_party>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Blinded</keyword>
  <keyword>Clonidine</keyword>
  <keyword>acetyl-salicylic acid (ASA)</keyword>
  <keyword>Perioperative vascular complications</keyword>
  <keyword>Noncardiac surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

